1-3 of 3
Don L Gibbons, MD, PhD
Close
Sort by
Journal Articles

Acquisition Of Compound BCR-ABL1 Alleles As A Mechanism Of Resistance To Ponatinib In Chronic Myeloid Leukemia

Don L Gibbons, MD, PhD, Sabrina Pricl, Paola Posocco, PhD, Erik Laurini, PhD, Maurizio Fermeglia, Moshe Talpaz, MD, Jorge E. Cortes, MD, Nicholas J. Donato, PhD, Alfonso Quintas-Cardama, MD
Journal: Blood
Blood (2013) 122 (21): 853.
https://doi.org/10.1182/blood.V122.21.853.853
Published: 2013
Journal Articles

The Novel BCR-ABL1 V304D Mutation Induces Pan-Tyrosine Kinase Inhibitor Resistance by a Unique Kinase Lateral Escape Mechanism and Is Associated with Very Poor Prognosis In Patients (PTS) with Chronic Myeloid Leukemia (CML).

Sabrina Pricl, PhD, Don L Gibbons, MD, PhD, Paola Posocco, PhD, Erik Laurini, PhD, Maurizio Fermeglia, Hagop M. Kantarjian, MD, Moshe Talpaz, MD, Jorge Cortes, MD, Matthew Young, PhD, Hanshi Sun, PhD, Luke F. Peterson, PhD, Nicholas Donato, PhD, Alfonso Quintás-Cardama, MD
Journal: Blood
Blood (2010) 116 (21): 3402.
https://doi.org/10.1182/blood.V116.21.3402.3402
Published: 2010
Journal Articles

In Silico modelling of Sensitivity to Novel Tyrosine Kinase Inhibitors of Highly Resistant Single and Polymutant BCR-ABL1 .

Sabrina Pricl, PhD, Don L Gibbons, MD, PhD, Paola Posocco, PhD, Erik Laurini, PhD, Maurizio Fermaglia, PhD, Hagop M. Kantarjian, MD, Moshe Talpaz, MD, Jorge Cortes, MD, Nicholas Donato, PhD, Alfonso Quintás-Cardama, MD
Journal: Blood
Blood (2010) 116 (21): 3388.
https://doi.org/10.1182/blood.V116.21.3388.3388
Published: 2010